In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery.
Keep Reading →
August 13 - Hedge Funds, News
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most undervalued biotech stocks to buy right now. Royalty Pharma Plc (NASDAQ:RPRX) announced on April 17 that its board of directors...
Keep Reading →
April 19 - News
On April 13, Tom Lee, Fundstrat's head of research, appeared on CNBC’s 'Power Lunch' to talk about his outlook on equities, what to expect in a wartime economy, and more.
Keep Reading →
April 18 - Hedge Funds, News
On February 12, Goldman Sachs raised its price target on Royalty Pharma plc (NASDAQ:RPRX) to $51 from $45 and maintained a Buy rating after strong Q4 results.
Keep Reading →
March 3 - News
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best cheap biotech stocks to buy now.
Keep Reading →
March 1 - News
On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
Keep Reading →
February 28 - Hedge Funds, News
Low-priced growth stocks, specifically those combining a low forward P/E ratio with strong or accelerating Earnings Per Share (EPS), offer a compelling blend of value and momentum...
Keep Reading →
February 28 - Hedge Funds, News
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best healthcare stocks under $50 to invest in.
Keep Reading →
February 10 - News
On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage...
Keep Reading →
February 9 - Hedge Funds, News
On the surface, the stock market seems totally binary, dancing to the tune of a president who likes to take the averages into his own hands and raise or lower them depending upon...
Keep Reading →
January 23 - Hedge Funds, News
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most profitable biotech stocks to buy.
Keep Reading →
October 28 - News
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Keep Reading →
October 27 - Hedge Funds, News
Royalty Pharma plc (NASDAQ:RPRX), a leader in biopharma royalties, made major strategic moves in September 2025.
Keep Reading →
September 23 - News
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United...
Keep Reading →
September 21 - Hedge Funds, News
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best affordable biotech stocks to invest in now. On September 12, TD Cowen analyst Michael Nedelcovych maintained a Buy rating ...
Keep Reading →
September 17 - News
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in...
Keep Reading →
September 16 - Hedge Funds, News
Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing in acquiring and managing royalties from marketed drugs, continues to demonstrate strong growth and ...
Keep Reading →
September 16 - News
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there...
Keep Reading →
September 15 - Hedge Funds, News
Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of the best performing stocks.
Keep Reading →
September 11 - News
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Keep Reading →
September 10 - Hedge Funds, News
Royalty Pharma plc (NASDAQ:RPRX) is one of the most undervalued and overlooked large-cap stocks.
Keep Reading →
August 29 - News
Royalty Pharma plc (NASDAQ:RPRX) is a leading buyer of biopharmaceutical royalties, holding interests in over 35 commercial products, including Trikafta, Trelegy, Evrysdi, and...
Keep Reading →
August 29 - News
Royalty Pharma plc (NASDAQ:RPRX) is a leading biopharmaceutical royalty company that invests in and acquires royalty interests in innovative drug products, partnering with biotech...
Keep Reading →
August 29 - News
A couple of days ago, the brokerage firm Jefferies increased its 2025 target for the S&P 500 index to 6,600, from its earlier target of 5,600.
Keep Reading →
August 28 - Hedge Funds, News
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
Keep Reading →
August 27 - Hedge Funds, News
Most Americans have endured the frustration of having their health insurance denied, often with no resolution even after contacting carriers by phone and email.
Keep Reading →
August 27 - Hedge Funds, News
Royalty Pharma Plc (NASDAQ:RPRX) is one of the top most undervalued biotech stocks to buy now.
Keep Reading →
August 12 - News
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the...
Keep Reading →
August 11 - Hedge Funds, News
Royalty Pharma plc (NASDAQ:RPRX) is one of the high-margin pharma stocks to buy now.
Keep Reading →
July 18 - News
The pharmaceutical sector continues to stand out as a resilient and highly profitable corner of the market, even amid global economic uncertainty.
Keep Reading →
July 18 - Hedge Funds, News
Healthcare prices and expenditures have been rising in the United States.
Keep Reading →
March 31 - Hedge Funds, News
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
Keep Reading →
March 30 - Hedge Funds, News
With ongoing inflation, economic uncertainty, and global tensions, more investors are looking for ways to protect their money while still earning steady returns.
Keep Reading →
March 24 - Hedge Funds, Industries, News
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may...
Keep Reading →
February 22 - Hedge Funds, Industries, News
Biotechnology stocks are among the most volatile in the market due to their high risk.
Keep Reading →
February 11 - Hedge Funds, News
Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of the most successful equity-focused hedge funds in the world.
Keep Reading →
January 22 - Hedge Funds, News
After two years of substantial gains to record highs, exhaustion in the US equity markets is slowly kicking in.
Keep Reading →
January 15 - Hedge Funds, News
Jim Cramer, host of Mad Money, recently shared some investment wisdom drawn from his four decades of experience.
Keep Reading →
December 26 - Hedge Funds, News
Jim Cramer in a latest program reiterated his view that the market is currently oversold and told investors about his methodology of analyzing market selling and buying indicators...
Keep Reading →
December 23 - News
With November coming to a close, while markets are focused on the future of artificial intelligence and the degree of profitability that AI firms can extract from their multi-...
Keep Reading →
December 4 - Hedge Funds, News
While the market has been on an upward trajectory for nearly two years now, the combination of seasonal trends, strong retail, and corporate activity, and positive market momentum...
Keep Reading →
November 26 - Hedge Funds, News
The US equities saw a strong move after the September jobs report exceeded the economists’ estimates.
Keep Reading →
October 6 - Hedge Funds, News
The stock market appears to be at a turning point. While major indexes are still hovering near record levels, there's been increased volatility this earnings season.
Keep Reading →
September 16 - Hedge Funds, News
We recently published a list of Jim Cramer’s Latest Lightning Round: Top 10 Stocks. Since Royalty Pharma plc (NASDAQ:RPRX) ranks 10th on the list, it deserves a deeper look...
Keep Reading →
August 26 - Hedge Funds, News
Jim Cramer in a latest program on CNBC said that the market has already priced in the expected positive comments from the Fed Chair Jerome Powell at the Jackson Hole event in ...
Keep Reading →
August 23 - Hedge Funds, News
Defensive stocks tend to remain stable and less affected by economic downturns.
Keep Reading →
August 16 - Hedge Funds, Industries, News
In the prior couple of years, experts and analysts were worried about a recession in the US and their best-case scenario was a soft landing.
Keep Reading →
July 2 - Hedge Funds, News
In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United Therapeutics, among others stand out for their innovative approaches...
Keep Reading →
March 17 - Lists, News
In this article, we discuss 5 most undervalued biotech stocks to buy according to hedge funds.
Keep Reading →
March 9 - News
Investing, for the most part, is all about the future. Each day thousands of investors flock to the stock market to try their hand at fate and become rich.
Keep Reading →
December 27 - Hedge Funds, News